$ISCO
International Stem Cell CORP

2023 Q1 Form 10-K Financial Statement

#000095017023010977 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $2.086M $2.430M $8.180M
YoY Change 3.27% 31.85% 13.99%
Cost Of Revenue $824.0K $1.136M $3.269M
YoY Change 13.66% 54.56% 11.38%
Gross Profit $1.262M $1.294M $4.911M
YoY Change -2.55% 16.79% 15.8%
Gross Profit Margin 60.5% 53.25% 60.04%
Selling, General & Admin $1.115M $1.108M $4.602M
YoY Change -1.59% -9.77% -15.82%
% of Gross Profit 88.35% 85.63% 93.71%
Research & Development $145.0K $125.0K $492.0K
YoY Change 5.84% -38.42% -29.21%
% of Gross Profit 11.49% 9.66% 10.02%
Depreciation & Amortization $51.00K $52.00K $218.0K
YoY Change -8.93% -22.39% -16.79%
% of Gross Profit 4.04% 4.02% 4.44%
Operating Expenses $1.260M $1.233M $5.094M
YoY Change 11.21% -13.84% -17.33%
Operating Profit $2.000K $61.00K -$183.0K
YoY Change -92.0% -118.89% -90.47%
Interest Expense $36.00K -$33.00K $135.0K
YoY Change -205.88% -19.51% 5.47%
% of Operating Profit 1800.0% -54.1%
Other Income/Expense, Net -$36.00K -$5.000K -$148.0K
YoY Change -205.88% -138.46% -114.48%
Pretax Income -$34.00K $23.00K -$331.0K
YoY Change 277.78% -106.55% -63.18%
Income Tax
% Of Pretax Income
Net Earnings -$34.00K $23.00K -$331.0K
YoY Change 277.78% -106.55% -63.18%
Net Earnings / Revenue -1.63% 0.95% -4.05%
Basic Earnings Per Share $0.00 -$0.04
Diluted Earnings Per Share $0.00 $0.00 -$0.04
COMMON SHARES
Basic Shares Outstanding 8.004M 8.004M 8.004M
Diluted Shares Outstanding 8.004M 8.004M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $943.0K $742.0K $742.0K
YoY Change 136.93% 333.92% 333.92%
Cash & Equivalents $943.0K $742.0K
Short-Term Investments
Other Short-Term Assets $26.00K $90.00K $90.00K
YoY Change -92.31% 429.41% -33.33%
Inventory $1.294M $1.384M $1.384M
Prepaid Expenses $285.0K $64.00K
Receivables $688.0K $747.0K $747.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.236M $2.963M $2.963M
YoY Change 9.32% 26.95% 26.95%
LONG-TERM ASSETS
Property, Plant & Equipment $232.0K $248.0K $975.0K
YoY Change -33.33% -35.42% -22.12%
Goodwill
YoY Change
Intangibles $858.0K $878.0K
YoY Change -7.48%
Long-Term Investments
YoY Change
Other Assets $328.0K $319.0K $319.0K
YoY Change -22.82% -22.38% -22.38%
Total Long-Term Assets $2.105M $2.172M $2.172M
YoY Change -17.16% -16.85% -16.85%
TOTAL ASSETS
Total Short-Term Assets $3.236M $2.963M $2.963M
Total Long-Term Assets $2.105M $2.172M $2.172M
Total Assets $5.341M $5.135M $5.135M
YoY Change -2.91% 3.82% 3.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $351.0K $322.0K $322.0K
YoY Change -44.72% -36.61% -36.61%
Accrued Expenses $632.0K $508.0K $738.0K
YoY Change -9.84% 25.74% 26.59%
Deferred Revenue
YoY Change
Short-Term Debt $3.357M $3.325M $3.325M
YoY Change 4.09% 12.98% 12.98%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.831M $4.635M $4.635M
YoY Change 0.42% 8.19% 8.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $656.0K $720.0K $720.0K
YoY Change -26.79% -24.21% -24.21%
Total Long-Term Liabilities $656.0K $720.0K $720.0K
YoY Change -26.79% -24.21% -24.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.831M $4.635M $4.635M
Total Long-Term Liabilities $656.0K $720.0K $720.0K
Total Liabilities $5.487M $5.355M $5.355M
YoY Change -3.85% 2.31% 2.31%
SHAREHOLDERS EQUITY
Retained Earnings -$110.4M -$110.3M
YoY Change 0.36% 0.26%
Common Stock $8.000K $8.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.446M -$4.520M -$220.0K
YoY Change
Total Liabilities & Shareholders Equity $5.341M $5.135M $5.135M
YoY Change -2.91% 3.82% 3.82%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$34.00K $23.00K -$331.0K
YoY Change 277.78% -106.55% -63.18%
Depreciation, Depletion And Amortization $51.00K $52.00K $218.0K
YoY Change -8.93% -22.39% -16.79%
Cash From Operating Activities $216.0K $79.00K $332.0K
YoY Change -1039.13% -125.0% -125.6%
INVESTING ACTIVITIES
Capital Expenditures $15.00K $3.000K $1.000K
YoY Change -116.67% -95.65%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$15.00K -$3.000K -$11.00K
YoY Change -83.33% -75.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 250.0K
YoY Change -100.0% -69.66%
NET CHANGE
Cash From Operating Activities 216.0K 79.00K 332.0K
Cash From Investing Activities -15.00K -3.000K -11.00K
Cash From Financing Activities 0.000 0.000 250.0K
Net Change In Cash 201.0K 76.00K 571.0K
YoY Change -19.6% -122.75% -210.23%
FREE CASH FLOW
Cash From Operating Activities $216.0K $79.00K $332.0K
Capital Expenditures $15.00K $3.000K $1.000K
Free Cash Flow $201.0K $76.00K $331.0K
YoY Change -973.91% -125.5% -125.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 isco Paycheck Protection Program Loan Forgiveness Period
PaycheckProtectionProgramLoanForgivenessPeriod
P168D
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001355790
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2021 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
0-51891
CY2022 dei Entity Registrant Name
EntityRegistrantName
INTERNATIONAL STEM CELL CORPORATION
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-4494098
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
9745 Businesspark Ave
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92131
CY2022 dei City Area Code
CityAreaCode
760
CY2022 dei Local Phone Number
LocalPhoneNumber
940-6383
CY2022 dei Security12g Title
Security12gTitle
Common Stock, $0.001 par value per share
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
1532606
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8004389
CY2022 dei Trading Symbol
TradingSymbol
ISCO
CY2022 dei Auditor Name
AuditorName
BDO USA, LLP
CY2022 dei Auditor Location
AuditorLocation
San Diego, California
CY2022 dei Auditor Firm
AuditorFirmId
243
CY2022Q4 us-gaap Cash
Cash
742000
CY2021Q4 us-gaap Cash
Cash
171000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
747000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
844000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1384000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1184000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
90000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
135000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2963000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2334000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
286000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
372000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
248000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
384000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
878000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
949000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
727000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
868000
CY2022Q4 isco Deposits And Other Assets
DepositsAndOtherAssets
33000
CY2021Q4 isco Deposits And Other Assets
DepositsAndOtherAssets
39000
CY2022Q4 us-gaap Assets
Assets
5135000
CY2021Q4 us-gaap Assets
Assets
4946000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
322000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
508000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
508000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
404000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
230000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
179000
CY2022Q4 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2021Q4 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
3325000
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
2943000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4635000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4284000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
720000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
950000
CY2022Q4 us-gaap Liabilities
Liabilities
5355000
CY2021Q4 us-gaap Liabilities
Liabilities
5234000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8004389
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8004389
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8004389
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8004389
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105812000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
105413000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110345000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110014000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4520000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-4588000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5135000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4946000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8180000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7176000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
3269000
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
2935000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3357000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4084000
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1245000
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1383000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
492000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
695000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
8363000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
9097000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-183000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-1921000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1137000
CY2022 us-gaap Interest Expense
InterestExpense
135000
CY2021 us-gaap Interest Expense
InterestExpense
128000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-148000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1022000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-331000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-899000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8004000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8004000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7833000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7833000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-4333000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
644000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-899000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-4588000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
399000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-331000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-4520000
CY2022 us-gaap Profit Loss
ProfitLoss
-331000
CY2021 us-gaap Profit Loss
ProfitLoss
-899000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
218000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
262000
CY2022 isco Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
141000
CY2021 isco Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
289000
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
250000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
399000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
644000
CY2021 isco Gain On Forgiveness Of Debt
GainOnForgivenessOfDebt
1137000
CY2022 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
132000
CY2021 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
118000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-97000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
441000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
114000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
268000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-45000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39000
CY2022 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-6000
CY2021 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-24000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-186000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
148000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
104000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
17000
CY2022 isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-179000
CY2021 isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-342000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
332000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1297000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10000
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
22000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45000
CY2021 isco Proceeds From Paycheck Protection Program Loan Amount
ProceedsFromPaycheckProtectionProgramLoanAmount
474000
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
250000
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
350000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
250000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
824000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
571000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-518000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
689000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
742000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
3000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
5000
CY2021 isco Gain On Forgiveness Of Debt
GainOnForgivenessOfDebt
1137000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
479000
CY2021 isco Right Of Use Asset Reduction Related To Operating Lease Termination
RightOfUseAssetReductionRelatedToOperatingLeaseTermination
196000
CY2022 isco Patent License Costs Included In Accrued Liabilities
PatentLicenseCostsIncludedInAccruedLiabilities
2000
CY2021 isco Patent License Costs Included In Accrued Liabilities
PatentLicenseCostsIncludedInAccruedLiabilities
6000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110300000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), allowance for excess and obsolete inventories, and stock option awards using the Black-Scholes option valuation model. Actual results could differ from those estimates.</span></p>
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2022 isco Number Of Business Units
NumberOfBusinessUnits
2
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3000
CY2008Q2 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2008Q2 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2008Q2 isco Specified Amount Of Revenue To Be Utilized First For Advances
SpecifiedAmountOfRevenueToBeUtilizedFirstForAdvances
250000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2022 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P15Y
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
498000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
507000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1194000
CY2022 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the biomedical products market and anti-aging products market. The biomedical market segment markets and sells primary human cell research products with two product categories, cells and media, which are sold both domestically within the United States and internationally. The anti-aging market segment markets and sells a line of skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while professional sales are to spas, salons and other skincare providers
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2022Q4 isco Number Of Products Categories
NumberOfProductsCategories
2
CY2022 isco Number Of Sales Channels
NumberOfSalesChannels
2
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
747000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
844000
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022 isco Product Return Guarantee Period
ProductReturnGuaranteePeriod
P30D
CY2022 isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2021 isco Allowance For Sales Return
AllowanceForSalesReturn
0
CY2022Q4 isco Financial Assets Fair Value Disclosure
FinancialAssetsFairValueDisclosure
0
CY2022 us-gaap Advertising Expense
AdvertisingExpense
220000
CY2021 us-gaap Advertising Expense
AdvertisingExpense
165000
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
983000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
2307000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
2082000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
637000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Concentrations</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> major customer accounted for approxim</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, of product sales. As of December 31, 2022 and 2021, the customer accounted for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, of accounts receivable, net.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> No other single customer accounted for more than 10% of product sales or accounts receivable, net, for the years ended.</span></p>
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12537176
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10727749
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
615000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
592000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
526000
CY2022Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1670000
CY2021Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1556000
CY2022Q4 us-gaap Inventory Net
InventoryNet
1384000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1184000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
286000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
372000
CY2022Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1670000
CY2021Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1556000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2467000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2507000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2219000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2123000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
248000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
384000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
137000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
171000
CY2022 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
41000
CY2021 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
1000000.0
CY2022Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1286000
CY2021Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1277000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
483000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
403000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
803000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
874000
CY2022Q4 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2021Q4 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
878000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
949000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
81000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
91000
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
250000
CY2022Q4 isco Finite Lived Pending Patents
FiniteLivedPendingPatents
57000
CY2021Q4 isco Finite Lived Pending Patents
FiniteLivedPendingPatents
108000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
82000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
82000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
80000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
76000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
73000
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
410000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
803000
CY2020Q2 isco Cares Act Of2020 Aid Amount
CARESActOf2020AidAmount
654000
CY2020Q2 isco Paycheck Protection Program Loan Maturity Period
PaycheckProtectionProgramLoanMaturityPeriod
P2Y
CY2020Q2 isco Paycheck Protection Program Loan Interest Rate
PaycheckProtectionProgramLoanInterestRate
0.01
CY2020Q2 isco Paycheck Protection Program Loan Deferred Payment Period
PaycheckProtectionProgramLoanDeferredPaymentPeriod
P10M
CY2021Q1 isco Cares Act Of2020 Aid Amount
CARESActOf2020AidAmount
474000
CY2021Q1 isco Paycheck Protection Program Loan Maturity Period
PaycheckProtectionProgramLoanMaturityPeriod
P5Y
CY2021Q1 isco Paycheck Protection Program Loan Interest Rate
PaycheckProtectionProgramLoanInterestRate
0.01
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2022 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
The holders of Series B, Series D, and Series G are entitled to one vote for each share of common stock into which it would convert.
CY2021Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
350000
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
250000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
609000
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y11M26D
CY2021Q4 isco Lease Costs Incurred Percentage
LeaseCostsIncurredPercentage
0.40
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 isco Class Of Warrant Or Right Issued Exercisable For Shares Of Common Stock
ClassOfWarrantOrRightIssuedExercisableForSharesOfCommonStock
11159995
CY2016Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15609580
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
399000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
644000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 isco Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.051
CY2021 isco Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.070
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.085
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.002
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.008
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.008
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.907
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.466
CY2022 isco Effective Income Tax Rate Reconciliation Forgiveness Of Ppp Loans
EffectiveIncomeTaxRateReconciliationForgivenessOfPPPLoans
0.000
CY2021 isco Effective Income Tax Rate Reconciliation Forgiveness Of Ppp Loans
EffectiveIncomeTaxRateReconciliationForgivenessOfPPPLoans
0.267
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.080
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.838
CY2022 isco Effective Income Tax Rate Reconciliation Adjustment To Nol For Erc
EffectiveIncomeTaxRateReconciliationAdjustmentToNolForErc
-0.406
CY2021 isco Effective Income Tax Rate Reconciliation Adjustment To Nol For Erc
EffectiveIncomeTaxRateReconciliationAdjustmentToNolForErc
0.000
CY2022 isco Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions
EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
-1.700
CY2021 isco Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions
EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
0.000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.037
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.025
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
953000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
953000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
953000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19266000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19603000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1993000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2899000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1252000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1153000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
425000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
235000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22936000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23890000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22936000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23890000
CY2022 isco Number Of Operating Leases
NumberOfOperatingLeases
3
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-12-31
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
11000
CY2021Q4 isco Percentage Of Increase Rent Per Annum Over Lease Term
PercentageOfIncreaseRentPerAnnumOverLeaseTerm
0.035
CY2021Q4 isco Percentage Of Base Rent Abated
PercentageOfBaseRentAbated
0.50
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
232000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
232000
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-12-31
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
247000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
247000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
727000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
950000
CY2022Q4 isco Finance Leases
FinanceLeases
0
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
278000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
456000
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
7000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
167000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
225000
CY2022 us-gaap Lease Cost
LeaseCost
452000
CY2021 us-gaap Lease Cost
LeaseCost
682000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
317000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
508000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
479000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y5M4D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y5M1D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1338
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1348
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
338000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
349000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
360000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
118000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1165000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
215000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
950000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
230000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
720000
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2022 isco Number Of Business Units
NumberOfBusinessUnits
2
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8180000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7176000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
8363000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
9097000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-183000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-1921000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-148000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1022000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-331000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-899000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8180000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7176000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
isco-20221231_cal.xml Edgar Link unprocessable
0000950170-23-010977-index-headers.html Edgar Link pending
0000950170-23-010977-index.html Edgar Link pending
0000950170-23-010977.txt Edgar Link pending
0000950170-23-010977-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
isco-20221231.htm Edgar Link pending
isco-20221231.xsd Edgar Link pending
isco-ex23_1.htm Edgar Link pending
isco-ex31_1.htm Edgar Link pending
isco-ex31_2.htm Edgar Link pending
isco-ex32_1.htm Edgar Link pending
isco-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
isco-20221231_def.xml Edgar Link unprocessable
isco-20221231_lab.xml Edgar Link unprocessable
isco-20221231_pre.xml Edgar Link unprocessable
isco-20221231_htm.xml Edgar Link completed
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending